>> As a chronic condition characterized by pelvic pain [1][2][3][4][5] , dysmenorrhea (pain during menstruation) 4,6,7 and dyspareunia (pain during sexual intercourse) 1,2,4,[7][8][9] , endometriosis is associated with significant individual (e.g. health-related quality of life impact) and societal burden (e.g. work productivity loss and healthcare costs).
Figure 1. Overview for derivation of 28-day aggregated scores ESD pelvic pain.
Note: Figure provides overview for derivation of ESD pelvic pain scores based on daily hypothetical individual patient data. Red data points indicate those days contributing to summary score. Derived score for 28-day period is highlighted in bold, respectively. 
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Convergent validity
The extent to which PRO scores correlate with scales that measure similar concepts and scales that measure dissimilar concepts (i.e., convergent and discriminant validity) .9) 5.9 (0-10) * Self-rated assessment of endometriosis-associated pain at its worst in the last 24 hours (using 0-10 NRS where 0 = no pain and 10 = pain as bad as you can imagine). ~ Counts not mutually exclusive. 
Overview of scoring algorithms
>> The ESD provides daily assessment of the three core symptoms of endometriosis (pelvic pain, pain associated with vaginal bleeding and dyspareunia). Aggregation of daily scores over a 28-day period enables derivation of a number of different scores for further evaluation. > 1. Pelvic pain is assessed on a daily basis using a series of 0-10 NRSs and can be used to derive the following scores (derivation of scores is explained in Figure 1 ):
• 28-day mean of worst pain (range 0-10)
• Mean of 7 worst days (range 0-10)
• Percentage of days with 'severe' pain ≥7 (range 0-100)
• Percentage of days with 'moderate' pain ≥4 (range 0-100) > 2. Pain associated with vaginal bleeding is evaluated by independent assessments of pain using a 0-10 NRS and vaginal bleeding using a 5-point verbal rating scale (days where bleeding is > light) and can be used to derive:
• 28-day mean of pain on bleeding days (range 0-10)
• Mean of pain on bleeding days only (range 0-10)
• Percentage of days with bleeding and pain ≥7 (range 0-100)
• Percentage of days with bleeding and pain ≥4 (range 0-100) > 3. Dyspareunia (pain associated with sexual intercourse) is assessed using a 0-10 NRS only on days with sexual intercourse in a 28-day period (range 0-10).
>> The EIS provides weekly assessment of the core impacts of endometriosis:
> Impact on physical activities assessed by 7 items using a 5-point verbal rating scale and recall period of the past week. 28-day scores derived (range 0-100) > Impact on emotional well-being assessed by 7 items using a 5-point verbal rating scale and recall period of the past week. 28-day scores derived (range 0-100)
Statistical Analyses
>> Data from the VALEPRO study was used to assess the reliability, validity and responsiveness of ESD and EIS scores (Table 2) . >> All analyses were specified a priori in a formally agreed SAP and conducted using SAS v9.4.
Results
>> Diverse samples of women with endometriosis, representative of the population to be included in planned clinical trials, were recruited (see Table 3 ).
Test-retest reliability
>> Collectively strong evidence of test-retest reliability of ESD and EIS scores was observed among patients defined as stable according to PGI-S ratings between weeks 4 to week 8 (n=120) and weeks 8 to week 12 (n=94) ( Table 4) .
Convergent validity
>> In general moderate to strong Pearson correlations between ESD and EIS scores and scores on concurrent measures demonstrate convergent validity (Table 5) .
Known-groups validity
>> ESD and EIS scores were effective at discriminating between known-groups of participants defined according to PGI-S, NRS, VAS and CGI-S scores. >> Significant differences were observed between groups.
>> ESD/EIS scores increased in a monotonic fashion with higher scores (indicating greater pain) among groups of patients classified as more severe by concurrent measures.
Responsiveness
>> Participants classified as 'improved' according to patient-reported (PGI-S, NRS and VAS) and clinician-reported (CGI-C) measures of disease severity all demonstrated a reduction (i.e. negative mean change) in ESD and EIS scores.
>> For all ESD and EIS scores (with the exception of dyspareunia scores) the magnitude of change observed in participants classified as 'improved' was significantly greater (p<.05) than those classified as 'no change/not improved'.
>> Findings were consistent regardless of the concurrent measure (PGI-S, NRS, VAS or CGI-C) used to categorize patients as 'improved' or 'no change/not improved'.
Limitations And Perspective
>> The study presented was observational and non-interventional in nature. Future work will need to determine scores for derivation of efficacy endpoints and determination of responsiveness, clinically meaningful differences and responder definitions for the ESD and the EIS in clinical trial populations.
Conclusions
>> There is strong evidence for the reliability and validity of scores derived from the ESD and EIS.
>> Future research will seek to further explore responsiveness and to establish definitions of meaningful change in ESD/EIS scores using data from clinical studies.
